Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GABRG2 | P18507 | 13/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 13/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 12/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 12/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 12/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 11/20 | 0.46 |
| ▸ | GABRA6 | Q16445 | 10/20 | 0.46 |
| ▸ | GABRA4 | P48169 | 5/20 | 0.46 |
| ▸ | GABRP | O00591 | 1/20 | 0.46 |
| ▸ | GABRD | O14764 | 1/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
| ▸ | GABRE | P78334 | 1/20 | 0.46 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.46 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.46 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31407736 | 1.00 | KDM4E (0.55) | KDM4EALDH1A1GABRG2GABRB3GABRA1 | |
| SCHEMBL13177597 | 0.87 | KDM4E (0.51) | KDM4EALDH1A1GABRG2GABRB3GABRA1 | |
| SCHEMBL27141575 | 0.84 | KDM4E (0.49) | KDM4EALDH1A1GABRG2GABRB3GABRA1 | |
| SCHEMBL13732052 | 0.82 | GABRG2 (0.49) | GABRG2GABRB3GABRA1GABRA2GABRA5 | |
| SCHEMBL8037078 | 0.81 | GABRG2 (0.47) | KDM4EALDH1A1GABRG2GABRB3GABRA1 | |
| SCHEMBL30978460 | 0.80 | MAPK1 (0.65) | KDM4EALDH1A1GABRG2GABRB3GABRA1 | |
| SCHEMBL109364 | 0.80 | MAPK1 (0.65) | KDM4EALDH1A1GABRG2GABRB3GABRA1 | |
| SCHEMBL31723056 | 0.79 | GABRG2 (0.57) | GABRG2GABRB3GABRA1GABRA2GABRA5 | |
| SCHEMBL30556510 | 0.79 | GABRG2 (0.46) | ALDH1A1GABRG2GABRB3GABRA1GABRA2 | |
| SCHEMBL15956221 | 0.79 | GABRG2 (0.46) | ALDH1A1GABRG2GABRB3GABRA1GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116323601-B | 2- (3-Pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl) -acetamide derivatives as transforming growth factor-beta receptor I/ALK5 inhibitors | 阿戈麦布西班牙股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12577228-B2 | Dihydrocyclopenta-isoquinoline-sulfonamide derivatives compounds | UCB Biopharma SRL (BE) | 2026-03-17 | — | — | US | disclosed |
| US-12577230-B2 | 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)- acetamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5 | AGOMAB SPAIN S.L.U. (ES) | 2026-03-17 | — | — | US | disclosed |
| EP-4695226-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | Pfizer Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4695271-A2 | A CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | Merck Sharp & Dohme LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4081296-B1 | DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS | UCB Biopharma SRL (BE) | 2026-02-11 | — | — | EP | disclosed |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667467-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| EP-1789410-A1 | METHYLENE DIPIPERIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-05-30 | — | — | EP | disclosed |
| EP-1756104-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR LIGANDS | Pfizer Limited (GB) | 2007-02-28 | — | — | EP | disclosed |
| US-20060247227-A1 | Substituted piperidines as histamine h3 receptor ligands | BAILEY JAMES M | 2006-11-02 | — | — | US | disclosed |
| EP-1646620-A1 | SUBSTITUTED PIPERIDINES AS HISTAMINE H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2006-04-19 | — | — | EP | disclosed |
| WO-2006029906-A1 | METHYLENE DIPIPERIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2006-03-23 | — | — | WO | disclosed |
| WO-2005111036-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR LIGANDS | PFIZER LIMITED (GB) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256135-A1 | Tetrahydronaphthyridine derivatives | LUNN GRAHAM | 2005-11-17 | — | — | US | disclosed |
| EP-1595881-A1 | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands | Pfizer Limited (GB) | 2005-11-16 | — | — | EP | disclosed |
| WO-2005014571-A1 | SUBSTITUTED PIPERIDINES AS HISTAMINE H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577230-B2 | 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)- acetamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5 | TGFBR1, TGFBR2, ACVR1 | KDM4E 3557/4885ALDH1A1 944/4885GABRG2 998/4885 |
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | CNR2, GRIN2C, GRIN2B | KDM4E 1975/4885ALDH1A1 1805/4885GABRG2 208/4885 |
| US-20050256135-A1 | Tetrahydronaphthyridine derivatives | HRH4, HRH3, HRH1 | KDM4E 3118/4885ALDH1A1 538/4885GABRG2 1242/4885 |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | KDM4E 671/4885ALDH1A1 2330/4885GABRG2 2305/4885 |
| US-12577228-B2 | Dihydrocyclopenta-isoquinoline-sulfonamide derivatives compounds | FCGR2A, FCER2, FCGR1A | KDM4E 2965/4885ALDH1A1 2200/4885GABRG2 560/4885 |
| US-20060247227-A1 | Substituted piperidines as histamine h3 receptor ligands | HRH3, HRH4, HRH1 | KDM4E 896/4885ALDH1A1 2611/4885GABRG2 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.